Septerna (NASDAQ:SEPN) Trading Down 6.1% – Here’s What Happened

Shares of Septerna, Inc. (NASDAQ:SEPN) fell 6.1% on Thursday . The stock traded as low as $45.28 and last traded at $45.2740. 391,444 shares were traded during trading, an increase of 9% from the average daily volume of 357,967 shares. The stock had previously closed at $48.19.

Analyst Ratings Changes

A number of analysts have weighed in on SEPN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. Guggenheim lifted their price target on shares of Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday. Wells Fargo & Company boosted their price objective on shares of Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday. Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a research note on Tuesday. Finally, HC Wainwright raised their target price on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Septerna has an average rating of “Moderate Buy” and a consensus price target of $51.33.

Septerna Trading Down 5.3%

The stock has a market capitalization of $2.13 billion, a P/E ratio of -84.55 and a beta of 2.29. The company’s 50-day moving average is $35.29 and its two-hundred day moving average is $29.40.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.59%. The firm had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. Sell-side analysts expect that Septerna, Inc. will post -1.59 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Samira Shaikhly sold 2,178 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the transaction, the insider directly owned 793 shares in the company, valued at approximately $27,897.74. The trade was a 73.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Daniel D. Long sold 3,334 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $34.47, for a total value of $114,922.98. Following the completion of the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,323,321.64. This trade represents a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 47,828 shares of company stock worth $1,584,314. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. TRV GP V LLC bought a new stake in shares of Septerna during the 2nd quarter worth about $208,160,143,000. TRV GP VI LLC bought a new position in shares of Septerna in the second quarter valued at approximately $141,048,460,000. BlackRock Inc. bought a new position in shares of Septerna in the second quarter valued at approximately $64,706,000. Goldman Sachs Group Inc. increased its stake in shares of Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in shares of Septerna during the first quarter valued at approximately $21,334,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.